healthcaretechoutlook

EarlySense Home-Monitoring Predicts Hospital Readmission Risk for Heart Failure Patients - Study

WALTHAM, MA: A study published in Journal of Telemedicine and Telecare has noted that EarlySense Home-Monitoring technology can predict effective hospital readmission risk for heart failure patients. The Researchers used a contactless under-the-mattress PS to monitor physiological vibrations resulting from breathing, pumping of the heart, and body movements, among individuals at home following hospitalization for heart failure (HF).

Under the leadership of Mr. Eiran Z Gorodeski of Cleveland Clinic, researchers performed an observational study at the homes of 30 patients who were discharged following heart failure. The study was based on the patients who were over the age of 18, had symptomatic HF as the admitting diagnosis, lived in Northeast Ohio, and slept on a mattress at home. The study was approved by Cleveland Clinic's Institutional Review Board.

Researchers monitored 29 patients via EarlySense Home-Monitoring technology for a total of 640 nights and founded that change in respiratory rate can predict hospital readmission risk for heart failure patients. EarlySense’s Home-Monitor is a piezoelectric sensor that converts mechanical deformations into electrical signals. It can detect subtle physiological vibrations resulting from breathing, pumping of the heart, and generalized body movements, across consumer-grade bed mattresses. Mathematical algorithms convert these signals into meaningful metrics including heart rate, respiratory rate and movement rate. Furthermore, the technology can report on breathing patterns, such as rapid and shallow breathing, and on behavioral patterns, such as amount of time spent in bed. EarlySense technology is also able to send signal data to a central monitoring station via LAN or Wi-Fi in a hospital. “These sensors are designed to assist clinicians’ early detection of adverse events in a non-invasive manner, providing the opportunity for intervention prior to hospitalization,” says Dalia Argaman, Vice President, Clinical and Regulatory Affairs, EarlySense.

New Editions